{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:25:23Z","timestamp":1790180723642,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Office of Vice Chancellor for Research and Graduate Studies at the University of Sharjah, UAE","award":["15010501014-P"],"award-info":[{"award-number":["15010501014-P"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.dsx.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T21:46:12Z","timestamp":1488836772000},"page":"S337-S341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females"],"prefix":"10.1016","volume":"11","author":[{"given":"Hayder","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Attlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Raigangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Madkour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Awadallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2017.03.012_bib0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/ATVBAHA.107.151092","article-title":"Metabolic syndrome pandemic","volume":"28","author":"Grundy","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0010","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2017.03.012_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/met.2008.0006","article-title":"The prevalence of the metabolic syndrome among the multiethnic population of the United Arab Emirates: a report of a national survey","volume":"6","author":"Malik","year":"2008","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.dsx.2017.03.012_bib0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dsx.2017.03.012_bib0025","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0030","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2017.03.012_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.dsx.2017.03.012_bib0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2017.03.012_bib0045","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0050","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.dsx.2017.03.012_bib0055","first-page":"523","article-title":"The Quebec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth","volume":"19","author":"Paradis","year":"2003","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0060","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjcard.2004.02.058","article-title":"The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health","volume":"93","author":"Victor","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0065","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/ATVBAHA.115.305688","article-title":"Role of insulin in the regulation of proprotein convertase subtilisin\/kexin type 9","volume":"35","author":"Miao","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0070","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0075","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1194\/jlr.P009860","article-title":"Fasting reduces plasma proprotein convertase, subtilisin\/kexin type 9 and cholesterol biosynthesis in humans","volume":"51","author":"Browning","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.dsx.2017.03.012_bib0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1194\/jlr.M055780","article-title":"Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol","volume":"56","author":"Ghosh","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.dsx.2017.03.012_bib0085","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0090","first-page":"1","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia","author":"Ferri","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.dsx.2017.03.012_bib0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.arteri.2015.11.001","article-title":"Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders","volume":"28","author":"Ibarretxe","year":"2016","journal-title":"Cl\u00ednica E Investig En Arterioscler Publicaci\u00f3n Of La Soc Espa\u00f1ola Arterioscler"},{"key":"10.1016\/j.dsx.2017.03.012_bib0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2013a new world-wide definition. a consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2017.03.012_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and?-Cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2017.03.012_bib0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase Subtilisin\/Kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2017.03.012_bib0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.dsx.2017.03.012_bib0125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2017.03.012_bib0130","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0140","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1172\/JCI29024","article-title":"Insulin resistance and atherosclerosis","volume":"116","author":"Semenkovich","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dsx.2017.03.012_bib0145","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.mcna.2007.06.012","article-title":"Insulin resistance as the underlying cause for the metabolic syndrome","volume":"91","author":"Lann","year":"2007","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.dsx.2017.03.012_bib0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/msj.20212","article-title":"Insulin resistance in obesity as the underlying cause for the metabolic syndrome","volume":"77","author":"Gallagher","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.dsx.2017.03.012_bib0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2016.02.018","article-title":"Targeting PCSK9 for therapeutic gains: have we addressed all the concerns?","volume":"248","author":"Banerjee","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2017.03.012_bib0160","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.clinbiochem.2014.03.022","article-title":"The effect of insulin on circulating PCSK9 in postmenopausal obese women","volume":"47","author":"Awan","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.dsx.2017.03.012_bib0165","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2010.10.028","article-title":"Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients","volume":"214","author":"Kappelle","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2017.03.012_bib0170","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.dsx.2017.03.012_bib0175","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402116303058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402116303058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T07:33:32Z","timestamp":1658043212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402116303058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":35,"alternative-id":["S1871402116303058"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2017.03.012","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}